(NASDAQ: RAPT) Rapt Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.
Rapt Therapeutics's earnings in 2025 is -$116,509,000.On average, 3 Wall Street analysts forecast RAPT's earnings for 2025 to be -$37,813,068, with the lowest RAPT earnings forecast at -$47,623,928, and the highest RAPT earnings forecast at -$20,835,468. On average, 3 Wall Street analysts forecast RAPT's earnings for 2026 to be -$35,772,515, with the lowest RAPT earnings forecast at -$46,301,041, and the highest RAPT earnings forecast at -$29,268,872.
In 2027, RAPT is forecast to generate -$37,619,596 in earnings, with the lowest earnings forecast at -$55,561,249 and the highest earnings forecast at -$19,677,942.